Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma.

@article{Ansell2004PhaseIO,
  title={Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma.},
  author={S. Ansell and J. Byrd and S. Horwitz and P. Borchmann and A. Engert and R. Strair and K. Khan and S. Fischkoff and M. Yellin},
  journal={Blood},
  year={2004},
  volume={104},
  pages={2636-2636}
}
  • S. Ansell, J. Byrd, +6 authors M. Yellin
  • Published 2004
  • Medicine
  • Blood
  • Background: MDX-060 is a fully human anti-CD30 IgG1k monoclonal antibody that induces Fc-receptor mediated killing of CD30 expressing cell lines and inhibits the growth of CD30-expressing tumor cells in a murine xenograft model. We previously reported data from the first 31 patients in a Phase I/II open-label, dose escalation study of MDX-060 in patients with relapsed or refractory CD30+ lymphomas. The purpose of the study is to determine the safety and tolerability profile of the drug, and to… CONTINUE READING
    19 Citations

    Topics from this paper.

    Immunotherapy of Hodgkin's lymphoma
    • 11
    Newer monoclonal antibodies for hematological malignancies.
    • 72
    • PDF
    Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.
    • H. Gerber
    • Medicine
    • Biochemical pharmacology
    • 2010
    • 29
    Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma
    • 126
    Current treatment and immunotherapy of Hodgkin's lymphoma.
    • 47
    • PDF
    Therapy of relapsed Hodgkin lymphoma.
    • 13
    Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
    • N. Bartlett
    • Medicine
    • Hematology. American Society of Hematology. Education Program
    • 2005
    • 14
    • PDF